Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms.
carcinoid syndrome
functioning syndrome
gastrinoma
insulinoma
neuroendocrine neoplasm
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
6
11
2023
pubmed:
14
6
2023
entrez:
13
6
2023
Statut:
ppublish
Résumé
Neuroendocrine neoplasms are a unique form of malignancies as they can be accompanied by specific functioning hormonal syndromes that can impair survival and quality of life in patients. Functioning syndromes are defined by the combination of specific clinical signs and symptoms in combination with inappropriately elevated circulating levels of hormones. Clinicians should remain vigilant for the presence of functioning syndromes in neuroendocrine neoplasm patients at presentation as well as during follow-up. The correct diagnostic work-up should be initiated in cases of clinical suspicion of a neuroendocrine neoplasm-associated functioning syndrome. Management of a functional syndrome includes options from supportive, surgical, hormonal and antiproliferative treatment modalities. Here, we review the patient and tumour characteristics for each functioning syndrome that should be taken into account when deciding the optimum treatment strategy in neuroendocrine neoplasm patients.
Identifiants
pubmed: 37311669
pii: S1521-690X(23)00061-1
doi: 10.1016/j.beem.2023.101787
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101787Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest JH has received speaker or consultancy fees from Novartis, Ipsen and Serb. WWH has received travel or speaker fees from Novartis, Ipsen and Advanced Accelerator Applications, research funds from Ipsen and is on the Advisory Boards of Novartis and of Ipsen.